VanEck Vectors Environmental Services ETF (EVX) Stock Price

40.72 ▲ +0.56 (+1.39%)
Open: 39.99 Vol: 13.7K Day's range: 39.91 - 40.72 Oct 22, 16:00 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
EVX Technical Analysis
5 mins 30 mins Hourly Daily Weekly
BUY BUY BUY BUY BUY
  5 mins 30 mins Hourly Daily Weekly
MA5 39.86▲ 39.86▲ 39.86▲ 40.14▲ 39.62▲
MA10 39.65▲ 39.65▲ 39.65▲ 39.79▲ 40.01▲
MA20 39.32▲ 39.34▲ 39.37▲ 39.44▲ 40.46▲
MA50 39.79▲ 39.93▲ 40.06▲ 40.03▲ 39.91▲
MA100 40.54▲ 40.46▲ 40.53▲ 40.32▲ 38.43▲
MA200 40.71▲ 40.42▲ 40.30▲ 40.19▲ 34.96▲
  5 mins 30 mins Hourly Daily Weekly
MACD 0.178▲ 0.183▲ 0.184▲ 0.192▲ -0.118▼
RSI 67.715▲ 66.326▲ 65.187▲ 67.305▲ 55.119▲
STOCH 73.338     73.338     73.338     90.637▲ 29.839    
WILL %R 0.000▲ 0.000▲ 0.000▲ 0.000▲ -31.176    
CCI 209.600▲ 209.600▲ 209.855▲ 158.248▲ 8.952    
Latest Filters Detected On EVX
MA $EVX Price Crossed Above MA(200) Set Alert
▲ BREAK $EVX Price Breaks 30 Days High Set Alert
▲ BREAK $EVX Price Breaks 20 Days High Set Alert
▲ BREAK $EVX Price Breaks 10 Days High Set Alert
CDL $EVX Engulfing Candlestick Pattern Detected Set Alert
VanEck Vectors Environmental Services ETF News
Evaxion reports 89% T-cell response at three years
Friday, October 23, 2026 12:47 AM
Evaxion reports sustained three-year responses in its Phase 2 EVX-01 melanoma trial, with 89% T-cell target recognition and no tumor progression in.
Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
Thursday, October 22, 2026 05:00 PM
EVX-01 induced an immune response in all patients, with 86% of the vaccine neoantigens generating potent specific T-cell responses as measured at the two-year follow-up. Analyses of additional samples ...
Evaxion stock surges on 3-year melanoma vaccine trial data
Monday, October 19, 2026 09:58 AM
Evaxion AS ADR (NASDAQ:EVAX) shares jumped 21.6% on Monday following the company's announcement of three-year data from its EVX-01 phase 2 trial in patients with advanced melanoma.
EVX historical stock data
date open high low close volume
22/10/26 39.99 40.72 39.91 40.72 13,700
21/10/26 40.26 40.26 40.10 40.16 5,600
20/10/26 39.79 40.13 39.75 40.13 4,400
19/10/26 39.93 39.96 39.75 39.80 7,300
16/10/26 40.12 40.12 39.71 39.87 2,900
15/10/26 39.55 39.90 39.45 39.90 11,100
14/10/26 39.50 39.53 39.30 39.53 7,600
13/10/26 39.43 39.46 39.36 39.46 2,500
12/10/26 39.10 39.40 39.10 39.23 5,500
09/10/26 39.13 39.175 38.99 39.1339 3,774
Quote Details
52wk Low:36.444
52wk High:42.44
Vol:13.7K
Avg Vol(3m):134.6K
1Y Chng:+10.20%
1M Chng:+1.95%
Add to Watch List
More Information
Sector N/A
Index N/A
Market Cap. 0.00